ZA200807800B - Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency - Google Patents

Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency

Info

Publication number
ZA200807800B
ZA200807800B ZA200807800A ZA200807800A ZA200807800B ZA 200807800 B ZA200807800 B ZA 200807800B ZA 200807800 A ZA200807800 A ZA 200807800A ZA 200807800 A ZA200807800 A ZA 200807800A ZA 200807800 B ZA200807800 B ZA 200807800B
Authority
ZA
South Africa
Prior art keywords
prophylaxis
collagen
treatment
omigapil
ynylamine
Prior art date
Application number
ZA200807800A
Other languages
English (en)
Inventor
Meier Thomas
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Publication of ZA200807800B publication Critical patent/ZA200807800B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
ZA200807800A 2006-04-05 2008-09-10 Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency ZA200807800B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007217A EP1842539A1 (en) 2006-04-05 2006-04-05 Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency

Publications (1)

Publication Number Publication Date
ZA200807800B true ZA200807800B (en) 2009-06-24

Family

ID=36190429

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807800A ZA200807800B (en) 2006-04-05 2008-09-10 Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency

Country Status (16)

Country Link
US (1) US7875648B2 (xx)
EP (2) EP1842539A1 (xx)
JP (1) JP4972156B2 (xx)
AT (1) ATE530181T1 (xx)
AU (1) AU2007236161B2 (xx)
CA (1) CA2648155C (xx)
CY (1) CY1112132T1 (xx)
DK (1) DK2004176T3 (xx)
ES (1) ES2371627T3 (xx)
MX (1) MX2008012867A (xx)
NZ (1) NZ571129A (xx)
PL (1) PL2004176T3 (xx)
PT (1) PT2004176E (xx)
SI (1) SI2004176T1 (xx)
WO (1) WO2007115776A1 (xx)
ZA (1) ZA200807800B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757284A1 (en) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
US9937144B2 (en) 2013-01-30 2018-04-10 The Johns Hopkins University Treatment of drug abuse by preventing GAPDH nitrosylation
WO2022258629A1 (en) 2021-06-07 2022-12-15 Katholieke Universiteit Leuven Idebenone in the treatment of drug resistant epilepsy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780244A (en) * 1993-09-27 1998-07-14 La Jolla Cancer Research Foundation Changes in laminin subunit composition are diagnostic of Fukuyama congenital muscular dystrophy
US5863743A (en) * 1994-08-12 1999-01-26 University Of Iowa Research Foundation Merosin deficiency-type congenital muscular dystrophy
ES2160790T3 (es) 1995-02-08 2001-11-16 Novartis Ag 10-aminoalifatil-dibenzo(b,f)oxepinas de accion antineurodegenerativa.
AR008371A1 (es) * 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
US7078379B2 (en) * 2002-06-03 2006-07-18 Santhera Pharmaceuticals (Schweiz) Gmbh Treatment of congenital muscular dystrophies
JP2006516580A (ja) 2003-01-29 2006-07-06 ノバルティス アクチエンゲゼルシャフト 眼の変性疾患の処置のための１０−アミノアリファチル−ジベンズ［ｂ，ｆ］オキセピンの使用
PE20050487A1 (es) 2003-11-06 2005-10-07 Novartis Ag Composiciones farmaceuticas estabilizadas
EP1757284A1 (en) 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy

Also Published As

Publication number Publication date
CA2648155C (en) 2011-11-15
JP2009532404A (ja) 2009-09-10
CA2648155A1 (en) 2007-10-18
AU2007236161B2 (en) 2009-12-10
NZ571129A (en) 2011-01-28
EP2004176B1 (en) 2011-10-26
EP2004176A1 (en) 2008-12-24
JP4972156B2 (ja) 2012-07-11
US20090176867A1 (en) 2009-07-09
PL2004176T3 (pl) 2012-03-30
US7875648B2 (en) 2011-01-25
PT2004176E (pt) 2011-11-23
WO2007115776A1 (en) 2007-10-18
SI2004176T1 (sl) 2012-01-31
ATE530181T1 (de) 2011-11-15
AU2007236161A1 (en) 2007-10-18
EP1842539A1 (en) 2007-10-10
CY1112132T1 (el) 2015-11-04
DK2004176T3 (da) 2012-02-06
ES2371627T3 (es) 2012-01-05
MX2008012867A (es) 2008-10-13

Similar Documents

Publication Publication Date Title
IN2012DN01233A (xx)
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2012007868A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
HK1149258A1 (en) Compounds
GB0722077D0 (en) Compounds
WO2007135529A3 (en) Azabenzimidazolyl compounds as mglur2 potentiators
NO20092103L (no) Tetrahydrocyklopenta[B]indolforbindelser som androgenreseptormodulatorer
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
MY151986A (en) Adamantyl diamide derivatives and uses of same
TW200639156A (en) New compounds
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
ZA200806778B (en) N-Hydroxyacrylamide compounds
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2006077024A3 (en) 5-aminoindole derivatives
TNSN08369A1 (en) Benzimidazole derivatives
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MX2012004835A (es) Derivados de espirolactama y usos de los mismos.
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
ZA200807800B (en) Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
TW200800993A (en) Organic compounds